Tests semaglutide with nicotine patches to help adults with diabetes quit smoking
Tests semaglutide alongside nicotine replacement in adults with diabetes who smoke.
Plain-language title generated from the registry record
Registry title: Semaglutide for Smoking Cessation in Patients With Diabetes
Key facts
- Where
- Ottawa, CanadaSee the site
- Phase
- Phase 3
Where in Canada
- University of Ottawa Heart InstituteOttawa, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ottawa Heart Institute Research Corporation
- Trial code
- NCT07059377
- Record updated
- 8 September 2026
- Original description
To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.Read full original descriptionShow less
Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial
To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.
Inclusion: Adults (18 years or older) with type 2 diabetes; Currently residing in Ontario; Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months; Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months; Have not used GLP-1 receptor agonists in the past six months; Able to provide informed consent.
Exclusion: Use of a DPP-IV inhibitor within the last 7 days; Initiation of a new diabetes medication within the last 3 months; As per the product monograph, participants with the following diagnoses or disorders will be excluded; Personal or family history of medullary thyroid cancer; Personal or family history of Multiple Endocrine Neoplasia syndrome type 2; Type I diabetes; Acute pancreatitis or pancreatic cancer; Acute, chronic or end-stage renal failure; Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French); Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year); Pregnant or breastfeeding individuals; Contraindication to NRT or GLP-1 RA; Current daily use of NRT or a GLP1 RA; Use of bupropion, cytisine, and varenicline within the last 7 days; Diabetic ketoacidosis; Tachyarrhythmias.